Linaprazan is a potassium-competitive acid blocker and an experimental therapeutic agent primarily investigated for the treatment of gastroesophageal reflux disease. This category contains a comprehensive… Read more
![Chemical structure of 5-(2-(8-((2,6-Dimethylbenzyl)(nitroso)amino)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamido)ethoxy)-5-oxopentanoic Acid](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F5-2-8-26-Dimethylbenzylnitrosoamino-23-dimethylimidazo12-apyridine-6-carboxamidoethoxy-5-oxopentanoic-Acid.png&w=3840&q=75)
![Chemical structure of 5-(2-(8-((2,6-Dimethylbenzyl)amino)-2,3-dimethyl-N-nitrosoimidazo[1,2-a]pyridine-6-carboxamido)ethoxy)-5-oxopentanoic Acid](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F5-2-8-26-Dimethylbenzylamino-23-dimethyl-N-nitrosoimidazo12-apyridine-6-carboxamidoethoxy-5-oxopentanoic-Acid.png&w=3840&q=75)










Linaprazan is a potassium-competitive acid blocker and an experimental therapeutic agent primarily investigated for the treatment of gastroesophageal reflux disease. This category contains a comprehensive selection of high-quality reference standards, including the active pharmaceutical ingredient, its nitroso-related impurities, and metabolic derivatives such as Linaprazan glurate. Analytical laboratories utilize these materials for rigorous impurity profiling, method validation, and routine quality control testing during pharmaceutical development. The inclusion of stable isotope labelled compounds, such as Linaprazan-d4, provides essential internal standards for mass spectrometry-based assays, ensuring accurate quantification and reliable pharmacokinetic studies. By offering a diverse range of structurally relevant reference substances, this collection supports the precise characterization of the drug substance and the monitoring of potential degradation products, facilitating compliance with safety and regulatory standards in pharmaceutical analysis.